What is Proteos?
Headquartered in Kalamazoo, Michigan, Proteos operates as a specialized contract service organization (CRO) that provides critical infrastructure for biopharmaceutical development. By leveraging diverse expression platforms—including mammalian, insect, and bacterial systems—the firm delivers high-quality recombinant proteins and antibodies essential for drug discovery and diagnostic applications. Their service model integrates comprehensive purification and analytical workflows, ensuring that clients receive tailored, high-fidelity biological materials. This technical proficiency, combined with a commitment to ethical and sustainable laboratory practices, has established Proteos as a reliable partner for organizations navigating the complexities of modern biotechnology research.
How much funding has Proteos raised?
Proteos has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Proteos
PPP
Public-Private Partnership
What's next for Proteos?
The infusion of capital from this recent financing round is expected to catalyze Proteos's next phase of growth, likely focusing on the scaling of its production capacity and the enhancement of its analytical service offerings. As the demand for high-quality biological reagents continues to rise, the company is strategically positioned to capture additional market share by optimizing its expression systems and streamlining its supply chain. Future initiatives will likely prioritize the integration of advanced automation in purification processes, further solidifying its reputation for precision and reliability. By maintaining its focus on customer-centric solutions, Proteos is poised to remain a pivotal player in the life sciences value chain, driving innovation through superior protein engineering and production excellence.
See full Proteos company page
